The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial.
Judge PK. et al, (2024), Nephrol Dial Transplant
Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease.
EMPA-KIDNEY Collaborative Group None. et al, (2024), N Engl J Med
Effects of Aspirin and Omega-3 Fatty Acids on Composite and Subdomain Scores from the NEI-VFQ-25 Questionnaire: The ASCEND-Eye Randomized Controlled Trial
SAMMONS E. et al, (2024), BMC Ophthalmology
ALDOSTERONE SYNTHASE INHIBITION WITH VICADROSTAT (BI 690517) TO REDUCE RISKS OF KIDNEY AND CARDIOVASCULAR DISEASE IN CHRONIC KIDNEY DISEASE: A RATIONALE FOR THE EASi-KIDNEY TRIAL
Judge P. et al, (2024), Nephrology Dialysis Transplantation
Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial
Mayne K. et al, (2024), Nephrology Dialysis Transplantation
Frailty, multimorbidity and polypharmacy: exploratory analyses of the effects of empagliflozin from the EMPA-KIDNEY trial
Mayne K. and HERRINGTON W., (2024), American Society of Nephrology. Clinical Journal
Effect of Fenofibrate on Progression of Diabetic Retinopathy.
Preiss D. et al, (2024), NEJM evidence, EVIDoa2400179 - EVIDoa2400179
Design, recruitment, and baseline characteristics of the LENS trial
PREISS D. et al, (2024), Diabetic Medicine
ASCEND-Eye: Effects of Omega-3 Fatty Acids on Diabetic Retinopathy
SAMMONS E. et al, (2023), Ophthalmology
Effects of Empagliflozin on Fluid Overload, Weight and Blood Pressure in Chronic Kidney Disease
Mayne K. et al, (2023), Journal of the American Society of Nephrology
Effects of empagliflozin on progression of chronic kidney disease: a pre-specified secondary analysis from the EMPA-KIDNEY trial
HAYNES R. et al, (2023), Lancet Diabetes and Endocrinology
Impact of Primary Kidney Disease on the Effects of Empagliflozin in Patients with Chronic Kidney Disease: Secondary Analyses of the EMPA-KIDNEY trial
Judge P. et al, (2023), Lancet Diabetes and Endocrinology
Impact of new cardiovascular events on quality of life and hospital costs in people with cardiovascular disease in the UK and US
MIHAYLOVA B. et al, (2023), Journal of the American Heart Association
ASCEND-Eye: Rationale, design and baseline characteristics for a sub-study of the ASCEND randomized trial, exploring the effects of aspirin and omega-3 fatty acids on diabetic retinopathy and age-related macular degeneration
SAMMONS E. et al, (2023), Contemporary Clinical Trials Communications
Empagliflozin in Patients with Chronic Kidney Disease
HERRINGTON W. et al, (2022), New England Journal of Medicine
Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease.
HPS3/TIMI55-REVEAL Collaborative Group None. et al, (2022), Eur Heart J, 43, 1416 - 1424
Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial
HERRINGTON W., (2022), Nephrology, Dialysis and Transplantation
Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group None., (2021), Lancet, 397, 605 - 612